ID   88-2FA
AC   CVCL_RA77
DR   Wikidata; Q54605458
RX   PubMed=1306323;
RX   PubMed=12111518;
CC   Population: Japanese.
CC   Doubling time: 99.2 +- 2.9 hours (PubMed=12111518).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_RA75 ! 88-2
OI   CVCL_RA76 ! 88-2F
OI   CVCL_RA78 ! 88-2T
SX   Male
AG   47Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 5
//
RX   PubMed=1306323; DOI=10.1620/tjem.168.375;
RA   Kobayashi, Shunsuke
RA   Fujimura, Shigefumi
RT   "Characterization and the clinical application of cultured human
RT   pulmonary carcinoma cells.";
RL   Tohoku J. Exp. Med. 168:375-386(1992).
//
RX   PubMed=12111518; DOI=10.1007/s005950200110;
RA   Kobayashi, Shunsuke
RA   Noda, Masashi
RA   Isogami, Katuhiko
RA   Hasumi, Toru
RT   "c-myc amplification and enhancement of sensitivity to cytosine
RT   arabinoside: an in vitro and in vivo study on four sublines
RT   established from a pulmonary adenocarcinoma.";
RL   Surg. Today 32:608-617(2002).
//